Role of IAPs in prostate cancer progression: Immunohistochemical study in normal and pathological (benign hyperplastic, prostatic intraepithelial neoplasia and cancer) human prostate

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Rodríguez Berriguete, Gonzalo ^a   Fraile, Benito ^a   de Bethencourt, Fermín R ^c   Prieto Folgado, Angela ^a   Bartolome, Nahikari ^a   Nuñez, Claudia ^a   Prati, Bruna ^a   Martínez Onsurbe, Pilar ^b   Olmedilla, Gabriel ^b   Paniagua, Ricardo ^a   Royuela, Mar ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR OF APOPTOSIS PROTEIN; INTERLEUKIN 1ALPHA; SURVIVIN; TUMOR NECROSIS FACTOR ALPHA; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN FUNCTION; WESTERN BLOTTING; DISEASE COURSE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSTATE; PROSTATE TUMOR;

AGED; CELL PROLIFERATION; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-1ALPHA; MALE; MIDDLE AGED; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77649302818     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-18     Document Type: Article

References (42)

1. Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol Endocrinol 1999, 13:376-384. 10.1210/me.13.3.376, 10076995.
2. Deveraux QL, Reed JC. IAP family proteins--suppressors of apoptosis. Genes Dev 1999, 13:239-252. 10.1101/gad.13.3.239, 9990849.
3. Salvesen GS, Dixit VM. Caspases: intracellular signaling by proteolysis. Cell 1997, 91:443-446. 10.1016/S0092-8674(00)80430-4, 9390553.
4. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004, 64:7183-7190. 10.1158/0008-5472.CAN-04-1918, 15492230.
5. Nuñez C, Cansino JR, Bethencourt F, Pérez-Utrilla M, Fraile B, Martínez-Onsurbe P, Olmedilla G, Paniagua R, Royuela M. TNF/IL-1/NIK/NF-kappa B transduction pathway: a comparative study in normal and pathological human prostate (benign hyperplasia and carcinoma). Histopathology 2008, 53:166-176. 10.1111/j.1365-2559.2008.03092.x, 18752500.
6. Royuela M, Rodríguez-Berriguete G, Fraile B, Paniagua R. TNF-alpha/IL-1/NF-kappaB transduction pathway in human cancer prostate. Histol Histopathol 2008, 23:1279-1290.
7. Nemoto T, Kitagawa M, Hasegawa M, Ikeda S, Akashi T, Takizawa T, Hirokawa K, Koike M. Expression of IAP family proteins in esophageal cancer. Exp Mol Pathol 2004, 76:253-259. 10.1016/j.yexmp.2004.01.001, 15126108.
8. Endo T, Abe S, Seidlar HB, Nagaoka S, Takemura T, Utsuyama M, Kitagawa M, Hirokawa K. Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol Immunother 2004, 53:770-776. 10.1007/s00262-004-0534-8, 15138717.
9. Espinosa M, Cantú D, Herrera N, Lopez CM, De la Garza JG, Maldonado V, Melendez-Zajgla J. Inhibitors of apoptosis proteins in human cervical cancer. BMC Cancer 2006, 6:45. 10.1186/1471-2407-6-45, 1403791, 16504151.
10. Krajewska M, Krajewski S, Banares S, Huang X, Turner B, Bubendorf L, Kallioniemi OP, Shabaik A, Vitiello A, Peehl D, Gao GJ, Reed JC. Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003, 9:4914-4925.
11. Lagacé M, Xuan JY, Young SS, McRoberts C, Maier J, Rajcan-Separovic E, Korneluk RG. Genomic organization of the X-linked inhibitor of apoptosis and identification of a novel testis-specific transcript. Genomics 2001, 77:181-188. 10.1006/geno.2001.6635, 11597143.
12. Shin H, Renatus M, Eckelman BP, Nunes VA, Sampaio CA, Salvesen GS. The BIR domain of IAP-like protein 2 is conformationally unstable: implications for caspase inhibition. Biochem J 2005, 385:1-10. 10.1042/BJ20041107, 1134667, 15485395.
13. Richter BW, Mir SS, Eiben LJ, Lewis J, Reffey SB, Frattini A, Tian L, Frank S, Youle RJ, Nelson DL, Notarangelo LD, Vezzoni P, Fearnhead HO, Duckett CS. Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol Cell Biol 2001, 21:4292-4301. 10.1128/MCB.21.13.4292-4301.2001, 87089, 11390657.
14. Roy N, Mahadevan MS, McLean M, Shutler G, Yaraghi Z, Farahani R, Baird S, Besner-Johnston A, Lefebvre C, Kang X. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995, 80:167-178. 10.1016/0092-8674(95)90461-1, 7813013.
15. Yamamoto K, Sakai H, Hadano S, Gondo Y, Ikeda JE. Identification of two distinct transcripts for the neuronal apoptosis inhibitory protein gene. Biochem Biophys Res Commun 1999, 264:998-1006. 10.1006/bbrc.1999.1615, 10544044.
16. Maier JK, Balabanian S, Coffill CR, Stewart A, Pelletier L, Franks DJ, Gendron NH, MacKenzie AE. Distribution of neuronal apoptosis inhibitory protein in human tissues. J Histochem Cytochem 2007, 55:911-923. 10.1369/jhc.6A7144.2007, 17510375.
17. Choi J, Hwang YK, Choi YJ, Yoo KE, Kim JH, Nam SJ, Yang JH, Lee SJ, Yoo KH, Sung KW, Koo HH, Im YH. Neuronal apoptosis inhibitory protein is overexpressed in patients with unfavorable prognostic factors in breast cancer. J Korean Med Sci 2007, 22:S17-23. 10.3346/jkms.2007.22.S.S17, 2694398, 17923748.
18. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999, 341:452-453. 10.1056/NEJM199908053410614, 10438269.
19. Saitoh Y, Yaginuma Y, Ishikawa M. Analysis of Bcl-2, Bax and Survivin genes in uterine cancer. Int J Oncol 1999, 15:137-141.
20. Yoshida H, Ishiko O, Sumi T, Matsumoto Y, Ogita S. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int J Oncol 2001, 19:537-542.
21. Ito T, Shiraki K, Sugimoto K, Yamanaka T, Fujikawa K, Ito M, Takase K, Moriyama M, Kawano H, Hayashida M, Nakano T, Suzuki A. Survivin promotes cell proliferation in human hepatocellular carcinoma. Hepatology 2000, 31:1080-1085. 10.1053/he.2000.6496, 10796883.
22. Shariat SF, Lotan Y, Saboorian H, Khoddami SM, Roehrborn CG, Slawin KM, Ashfaq R. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004, 100:751-757. 10.1002/cncr.20039, 14770431.
23. Amantana A, London CA, Iversen PL, Devi GR. X-linked inhibitor of apoptosis protein inhibition induces apoptosis and enhances chemotherapy sensitivity in human prostate cancer cells. Mol Cancer Ther 2004, 3:699-707.
24. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998, 17:3247-3259. 10.1038/sj.onc.1202569, 9916987.
25. Kishi H, Igawa M, Kikuno N, Yoshino T, Urakami S, Shiina H. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J Urol 2004, 171:1855-1860. 10.1097/01.ju.0000120317.88372.03, 15076293.
26. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006, 5:1087-1098. 10.1158/1535-7163.MCT-05-0375, 16731740.
27. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 2001, 34:207-212. 10.1007/s007950100017, 11956993.
28. Vischioni B, Valk P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G. Expression and localization of inhibitor of apoptosis proteins in normal human tissues. Hum Pathol 2006, 37:78-86. 10.1016/j.humpath.2005.09.022, 16360419.
29. Suh J, Rabson AB. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon?. J Cell Biochem 2004, 91:100-117. 10.1002/jcb.10729, 14689584.
30. Royuela M, De Miguel MP, Bethencourt FR, Fraile B, Arenas MI, Paniagua R. IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. Growth Factors 2000, 18:135-146. 10.3109/08977190009003239, 11019784.
31. Ricote M, García-Tuñón I, Bethencourt F, Fraile B, Onsurbe P, Paniagua R, Royuela M. The p38 transduction pathway in prostatic neoplasia. J Pathol 2006, 208:401-407. 10.1002/path.1910, 16369914.
32. Verhagen AM, Coulson EJ, Vaux DL. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol 2001, 2:REVIEWS3009. 10.1186/gb-2001-2-7-reviews3009, 139420, 11516343.
33. Shariat SF, Ashfaq R, Roehrborn CG, Slawin KM, Lotan Y. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol 2005, 174:2046-2050. 10.1097/01.ju.0000176459.79180.d1, 16217391.
34. Royuela M, Arenas MI, Bethencourt FR, Sánchez-Chapado M, Fraile B, Paniagua R. Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate. Hum Pathol 2002, 33:299-306. 10.1053/hupa.2002.32227, 11979370.
35. de Miguel MP, Royuela M, Bethencourt FR, Santamaría L, Fraile B, Paniagua R. Immunoexpression of tumour necrosis factor-alpha and its receptors 1 and 2 correlates with proliferation/apoptosis equilibrium in normal, hyperplasic and carcinomatous human prostate. Cytokine 2000, 12:535-538. 10.1006/cyto.1999.0585, 10857774.
36. McEleny KR, Watson RW, Coffey RN, O'Neill AJ, Fitzpatrick JM. Inhibitors of apoptosis proteins in prostate cancer cell lines. Prostate 2002, 51:133-140. 10.1002/pros.10061, 11948968.
37. Shariat SF, Roudier MP, Wilcox GE, Kattan MW, Scardino PT, Vessella RL, Erdamar S, Nguyen C, Wheeler TM, Slawin KM. Comparison of immunohistochemistry with reverse transcription-PCR for the detection of micrometastatic prostate cancer in lymph nodes. Cancer Res 2003, 63:4662-4670.
38. Kaur P, Kallakury BS, Sheehan CE, Fisher HA, Kaufman RP, Ross JS. Survivin and Bcl-2 expression in prostatic adenocarcinomas. Arch Pathol Lab Med 2004, 128:39-43.
39. Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005, 24:2474-2482. 10.1038/sj.onc.1208490, 15735703.
40. Chen CD, Sawyers CL. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 2002, 22:2862-2870. 10.1128/MCB.22.8.2862-2870.2002, 133743, 11909978.
41. Zou T, Rao JN, Guo X, Liu L, Zhang HM, Strauch ED, Bass BL, Wang JY. NF-kappaB-mediated IAP expression induces resistance of intestinal epithelial cells to apoptosis after polyamine depletion. Am J Physiol Cell Physiol 2004, 286:C1009-18. 10.1152/ajpcell.00480.2003, 15075199.
42. Jin HS, Lee DH, Kim DH, Chung JH, Lee SJ, Lee TH. cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways to regulate genotoxic stress-induced nuclear factor-kappaB activation. Cancer Res 2009, 69:1782-91. 10.1158/0008-5472.CAN-08-2256, 19223549.